ALBO News and Press, Albireo Pharma Inc. From 08/06/19

BOSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Wedbush PacGrow...

BOSTON, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10 a.m. EDT on August...

With several licenses acquired from well-known pharmaceutical companies, Mirum Pharmaceuticals ( MIRM ) is a name to be followed carefully after the IPO. The most appealing is its pipeline. The company owns two product candidates at Phase 3 of development and several candidates at Phase 2 of d...

Shares of Albireo Pharma (ALBO) have risen by over 50% since I originally initiated a position in the stock as our fourth idea for ROTY (when it was just getting underway in mid-2017). The stock price has risen by 27% since my subsequent update piece was published in November of 2017. Th...

In an update for investors, Albireo Pharma (NASDAQ: ALBO ) announces that enrollment in its Phase 3 clinical trial, PEDFIC 1 , evaluating odevixibat in pediatric patients with progressive familial intrahepatic cholestasis (PFIC) is over 50% completed. More news on: Albireo Pharma, Inc.,...

— Expects Odevixibat PEDFIC 1 Phase 3 Topline Data Mid-2020 — — Site Activated for Odevixibat PEDFIC 2 Expanded Open-Label Cohort — — Odevixibat Biliary Atresia Pivotal Trial Expected to Begin in 2020 — — Mov...

Market Assessment GlaxoSmithKline plc (GSK) is a large cap ($99B) commercial stage biopharma known for its innovative therapeutics for diverse disease states affecting many organ systems. GSK is not really a household name in reference to therapeutics for viral and non-viral liver diseases...

New Initiative to Create Awareness and Understanding of Life-Threatening Pediatric Liver Disease  Announced new PFIC Voices website, www.PFICvoices.com BOSTON, June 20, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver d...

Introduction Albireo ( ALBO ) is one or the only publicly-listed biopharma that has an orphan pediatric cholestatic liver diseases clinical program. Albireo through its unique drug pipeline employs a distinct mechanistic approach to dealing with the distressing adverse event of pruritus (i...

Albireo Pharma (NASDAQ: ALBO ) announces positive data from a Phase 2 clinical trial evaluating lead candidate odevixibat (A4250) in patients with three rare liver/bile duct disorders: biliary atresia, Alagille syndrome and progressive familial intrahepatic cholestasis. The results were pr...